cloudy.png
Friday November 15th, 2019 11:13AM

Key drug sales push Pfizer profit up 50 percent

By The Associated Press

Rising sales of most key drugs, lower one-time charges and reduced manufacturing costs helped drive Pfizer's second-quarter profit up 50 percent.

The top U.S. drugmaker beat Wall Street profit forecasts, tweaked its own 2017 forecast, and predicted numerous lucrative drugs will be approved over the next half-decade. Still, cheaper generic competition continues to gnaw away at Pfizer's revenue, which fell short of analyst expectations.

Meanwhile, CEO Ian Read told analysts during a conference call Tuesday that Pfizer is avoiding any big acquisitions — long its chief growth strategy — as it waits for the administration and Congress to enact tax reform. He said that would affect the valuation of assets at Pfizer and potential purchase targets.

The Viagra maker reported quarterly profit of $3.07 billion, or 51 cents per share, up from $2.05 billion, or 33 cents per share, a year earlier. Adjusted income of 67 cents per share beat analysts' average estimate by two cents.

The New York drugmaker posted revenue of $12.9 billion, down 2 percent and below forecasts for $13.02 billion.

Top sellers including new breast cancer drug Ibrance and blood thinner Eliquis produced higher sales, helping lift revenue from Pfizer's patented-protected drugs by 8 percent, to $7.67 billion. Pfizer's essential health segment, which sells older products that are mostly off patent, had sales drop 14 percent to $5.23 billion.

Their sales were led by Lipitor, the cholesterol-fighting pill that reigned as the world's top seller for a decade. Nearly six years after getting generic competition, Lipitor still ranks No. 7 in sales, at $445 million in the quarter, partly because a few newer drugs have produced lower-than-expected sales.

Some new medicines are coming, though. In May, Bavencio got U.S. approval for treating advanced bladder cancer, and Pfizer's drug for a type of leukemia could get approved this month. But new eczema treatment Eucrisa, approved in February, managed only $9 million in second-quarter sales.

Over the next five years, Pfizer expects to win approvals for up to 18 new drugs and a half-dozen "biosimilars," near-generic versions of complex injected drugs manufactured inside cells. However, Pfizer's first approved biosimilar — Inflectra, a near-copy of blockbuster immune disorder drug Remicade launched in November — had only $94 million in second-quarter sales. Pfizer executives said it only has a 2 percent market share as commercial insurers mainly are sticking with Remicade so far due to deals offered by its maker, Johnson & Johnson.

Sales at Pfizer's consumer health business edged up 1 percent, to $846 million.

Pfizer now expects adjusted full-year earnings of $2.54 to $2.60 per share, with the lower end up 4 cents from its May forecast. The company still expects 2017 revenue of $52 billion to $54 billion.

In afternoon trading, Pfizer shares were unchanged at $33.16.

___

Follow Linda A. Johnson at www.twitter.com/LindaJ_onPharma

  • Associated Categories: Associated Press (AP), AP Business, AP Business - Corporate News, AP Business - Industries, AP Business - Health Care
© Copyright 2019 AccessWDUN.com
All rights reserved. This material may not be published, broadcast, rewritten, or redistributed without permission.
Jordanian parliament repeals 'marry the rapist' clause
Jordan's parliament removes 'marry the rapist' clause from penal code in major victory for women's rights
7:33AM ( 22 minutes ago )
Lebanon: Syrian refugees hesitant to return despite opening
A committee of Syrian refugees in Lebanon's eastern border region says tens of thousands of them will remain where they are despite an arrangement offered to them to return to Syria
7:24AM ( 31 minutes ago )
Bank of England employees strike for first time in 50 years
Employees of the Bank of England have begun a three day strike over concerns around wages
7:07AM ( 49 minutes ago )
Associated Press (AP)
Indonesia lifts threat to ban encrypted app Telegram
Indonesia's information technology minister says the government will allow the encrypted messaging app Telegram to continue operating in Indonesia because it's taking steps to address "negative" content
6:08AM ( 1 hour ago )
Eurozone economy picked up speed in the second quarter
Europe's economic expansion kept on rolling and even picked up a little speed in the fourth quarter
5:46AM ( 2 hours ago )
Former Thai PM says she's innocent, asks for 'kindness'
Former Thai Prime Minister Yingluck Shinawatra has declared her innocence and asked for "kindness" from a court during closing arguments in a criminal negligence trial
5:45AM ( 2 hours ago )
AP Business
Asian stocks climb as more economic, earnings data due
Asian stock markets advance as investors look to fresh round of earnings reports, economic data for proof global economy is on right track
2:11AM ( 5 hours ago )
Asian stocks climb as more economic, earnings data due
Asian stock markets advance as investors prepare for fresh round of earnings reports and economic data
11:22PM ( 8 hours ago )
Hawaii allows first lab to begin testing medical marijuana
Hawaii has approved its first laboratory to begin testing samples of medical marijuana
10:09PM ( 9 hours ago )
AP Business - Corporate News
Jordanian parliament repeals 'marry the rapist' clause
Jordan's parliament removes 'marry the rapist' clause from penal code in major victory for women's rights
7:33AM ( 22 minutes ago )
Lebanon: Syrian refugees hesitant to return despite opening
A committee of Syrian refugees in Lebanon's eastern border region says tens of thousands of them will remain where they are despite an arrangement offered to them to return to Syria
7:24AM ( 31 minutes ago )
Bank of England employees strike for first time in 50 years
Employees of the Bank of England have begun a three day strike over concerns around wages
7:07AM ( 49 minutes ago )
UK presses tech firms to choke off online extremism
Britain's interior minister is traveling to California to press Internet firms to stem the flow of extremist content online
6:51AM ( 1 hour ago )
Police take 2 Venezuela opposition leaders from homes
Two of Venezuela's leading opposition figures were taken from their homes in the middle of the night by state security agents on Tuesday in President Nicolas Maduro's first moves against his enemies since a vote giving his government more power
6:30AM ( 1 hour ago )